Lucid Diagnostics Inc. - Common Stock (LUCD)

LUCD Q1 2026 Earnings Transcript

Lucid Diagnostics (NASDAQ:LUCD) reported first-quarter 2026 EsoGuard test volume above its pre-Medicare target range, while management said it continues to await a Medicare local coverage determination and is expanding efforts with the Department of Veterans Affairs, commercial payers and health sys

Lucid Diagnostics (LUCD) Earnings Transcript

The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer.

Lucid Diagnostics (LUCD) Q2 2025 results: Revenue $1.16M, EPS -$0.10, beating estimates. Processed 2,756 EsoGuard tests, maintains $30M+ cash. Stock up 2.26% pre-market.

A Needham analyst predicts that Lucid Diagnostics (NASDAQ: LUCD) will see a surge in testing volumes with expected Medicare reimbursement approval.

Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

On Stocktwits, sentiment for the stock climbed higher within the 'extremely bullish' zone late Wednesday, while message volume rose by more than 18%.